Innodem Neurosciences is a digital biomarker & AI company that specializes in the development of an eye tracking technology, ETNA™, that shows promising use for neurological assessment of the progression of various neurodegenerative and mental diseases. The ETNA™ technology is being trialed with patients living with various neurodegenerative and mental diseases, such as multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Friedreich Ataxia, and cancer-related cognitive impairment. Its patented ETNA™-MS technology is currently under regulatory review.